Al Gore (via last.fm)
Former Vice President Al Gore Endorses Trans-Pacific Collaboration to Promote Use of Patient Cells for Drug Discovery and Development and Cell-Based Therapies iZumi Bio, Inc., and Kyoto University‘s Center for iPS Cell Research and Application (CiRA), today announced a collaboration to promote the basic research, development and application of induced pluripotent stem (iPS) cell technology – a form of cellular reprogramming which originated in Japan – with the goal of advancing drug discovery and enabling cell-based therapies.
“Stem cell research holds great promise for the creation of new therapies that could revolutionize the treatment of disorders such
International Stem Cell Corporation announced that its Research and Development team has advanced its program to create a functional and transplantable human cornea by developing a new method to derive corneal endothelium-like cells from human pluripotent stem cells.
This work represents a significant step towards the creation of complete cornea tissue that can be used for transplantation and supports prior data showing indications of corneal endothelium generated by ISCO’s collaborators at Sankara Nethralaya Eye Hospital, India. Such cells by themselves may potentially promote wound healing and regeneration of the cornea and therefore could be used as a standalone medical treatment.
Image via Wikipedia
Don’t look for this just yet at your neighborhood clinic, but Minnesota scientists are pushing stem cell therapies into new frontiers — into territory that is so open that doctors and regulators still are shaping practices and policies as they go along.
In one breakthrough, researchers at Mayo Clinic in Rochester obtained stem cells derived from the bone marrow of heart disease patients and guided the cells to help heal, repair and regenerate damaged heart tissue. This is “landmark work,” said an editorial accompanying their research report in Monday’s Journal of the American College of Cardiology.
And last week,
(…) Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells, that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials. The REGEN trial is designed to test the safety and effectiveness of a composition of muscle stem cells that have been gene-modified to induce a greater than usual release of the SDF-1 protein. The SDF-1 protein is a molecule in the human body that, after an injury, is naturally released by most tissues to attract stem cells. The stem cells assist with the healing process.
Image via Wikipedia
SURGEONS from Southampton have developed a pioneering bone repair technique that could end the need for artificial hip replacements.
Six people have undergone the procedure which uses a their own stem cells to repair damaged hip joints. Only one operation has failed (…)
Under the procedure surgeons extract bone marrow from the back of a patients’ pelvis, then extract a layer of stem cells by spinning the marrow in a centrifuge.
The stem cells are then mixed with ground up bone donated from another patients discarded hip replacement (…)
Professor Richard Oreffo of Southampton University, one of those behind the research,